EVEREST MED(01952.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 5.94 million, loss narrowed by 97.62% YoY

NewTimeSpace News: August 19, 2026, EVEREST MED(01952.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 1.15 billion, increased by 157.29% YoY; Net Profit stood at loss of CNY 5.94 million, loss narrowed by 97.62% YoY; Profit Attributable to Shareholders stood at loss of CNY 5.94 million, loss narrowed by 97.62% YoY; Basic Earnings Per Share (EPS) stood at loss of CNY cents 2.

In terms of profitability, EVEREST MED Gross Profit changed from CNY 299.4 million in the same period last year to CNY 799.32 million in the current period, increased by CNY 499.92 million; gross profit margin changed from 67.11% in the same period last year to 69.64% in the current period, increased by 2.53 percentage points; net profit changed from loss of CNY 249.79 million in the same period last year to loss of CNY 5.94 million in the current period, increased by CNY 243.85 million; net profit margin changed from -55.99% in the same period last year to -0.52% in the current period, increased by 55.47 percentage points.

In terms of earnings quality, EVEREST MED Operating Profit changed from loss of CNY 262.56 million in the same period last year to CNY 56.43 million in the current period, increased by CNY 318.99 million; Operating Profit Margin changed from -58.85% in the same period last year to 4.92% in the current period, increased by 63.77 percentage points; Net Cash Flow from Operating Activities changed from cash outflow of CNY 181.47 million in the same period last year to cash outflow of CNY 272.51 million in the current period, decreased by CNY 91.04 million; Ratio of Net Cash Flow from Operating Activities to Total Operating Revenue changed from -40.68% in the same period last year to -23.74% in the current period, increased by 16.94 percentage points.

In terms of financial soundness, EVEREST MED Debt-to-Asset Ratio changed from 20.39% in the same period last year to 38.08% in the current period, increased by 17.69 percentage points; Total Equity changed from CNY 3.926 billion in the same period last year to CNY 5.229 billion in the current period, increased by CNY 1.3 billion; Cash and Cash Equivalents changed from CNY 1.297 billion in the same period last year to CNY 1.518 billion in the current period, increased by CNY 221.41 million; Current Liabilities changed from CNY 357.72 million in the same period last year to CNY 799.93 million in the current period, increased by CNY 442.21 million; Quick Ratio changed from 5.43 in the same period last year to 3.58 in the current period, decreased by 1.85 percentage points.

In terms of R&D investment focus, EVEREST MED R&D Expenses changed from CNY 195.22 million in the same period last year to CNY 256.06 million in the current period, increased by CNY 60.84 million; R&D to Total Revenue Ratio changed from 43.76% in the same period last year to 22.31% in the current period, decreased by 21.45 percentage points.

By the close of trading on August 18, 2026, EVEREST MED(01952) saw a gain of 0.9% in its share price, closing at HKD 29.28. During the session, it reached an intraday high of HKD 30.84. The full-day turnover stood at HKD 93.62 million, with the latest market capitalization at HKD 10.36 billion.

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.